Clinical Trials

Immunotherapy

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

LEARN MORE

Beyond First Line Therapy

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors

LEARN MORE

Chemotherapy

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (TOPAZ-1)

LEARN MORE

Beyond First Line Therapy

Phase IIb trial of pemigatinib in combination with atezolizumab and bevacizumab for treatment of advanced cholangiocarcinoma with FGFR2 fusion

LEARN MORE

Beyond First Line Therapy

Alliance EAY191-A6: A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations

LEARN MORE

Beyond First Line Therapy

GNS561-221-1

LEARN MORE

Beyond First Line Therapy

A Phase Ia/Ib Study of the Combination of the FGFR inhibitor Pemigatinib and the EGFR inhibitor Afatinib in Advanced Refractory Solid Tumors

LEARN MORE

Beyond First Line Therapy

A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumors (MAST).

LEARN MORE

Chemotherapy

Herizon BTC-302 An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard of care therapy alone for advanced HER2 positive biliary tract cancer

LEARN MORE

Beyond First Line Therapy

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

LEARN MORE

Beyond First Line Therapy

NCI/CTEP 10276: A Phase 1/2 Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

LEARN MORE

First Line Therapy

FIRST-308

LEARN MORE